» Optymalizacja antybiotykoterapii zakażeń dróg oddechowych w aspekcie programu ochrony antybiotyków

*Piotr Albrecht, Andrzej Radzikowski

Optymalizacja antybiotykoterapii zakażeń dróg oddechowych w aspekcie programu ochrony antybiotyków

Optimization of antibiotic therapy of respiratory tract infections in the aspect of the conservation programme of antibiotics

Klinika Gastroenterologii i Żywienia Dzieci Warszawskiego Uniwersytetu Medycznego
Kierownik Kliniki: prof. nadzw. dr hab. med. Andrzej Radzikowski

Summary

Key words:

Piśmiennictwo

1. European Commission. Communication From The Commission On A Community Strategy Against Antimicrobial Resistance, Brussels, 20.06.2001, COM (2001) 333 final, Volume 1. 2. Muller A et al.: European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe, 1998-2005. Euro Surveill. 2007; 12(41): pii=3284. 3. Hryniewicz W i wsp.: Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego - 2009, w druku. 4. Poses R et al.: The accuracy of experienced physician in probability estimates for patients with the sore throats: implications of decision making. JAMA 1985; 254: 925-929. 5. Komaroff A et al.: The prediction of streptococcal pharyngitis in adults.J Gen Intern Med 1986; 1: 1-7. 6. Gwaltney J, Bisno A: Pharyngitis. In: Principles and practice of infectious diseases. Mandell G, Bennett J, Dolin R. eds. 5th ed. Vol 1. Churchill Livingstone, 2000 pp. 656-662. 7. Gunnarsson R, Holm S, Soderstome M: The prevalence of beta-haemolytic streptococci in throat specimens from healthy children and adults: implications for clinical value of throat cultures. Scand J Prim Health Care 1997; 15: 149-155. 8. Centor R et al.: The diagnosis of strep throat in adults in the emergency room. Med Decis Making 1981; 1: 239-246. 9. McIssac W et al.: The validity of a sore throat score in family practice. CMAJ 2000; 163: 811-815. 10. Geber M: Comparison of throat cultures and rapid strep test for diagnosis of streptococcal pharyngitis. Pediatr Infect Dis J 1989; 8: 820-824. 11. Schwartz R: Evaluation of rapid streptococcal detection tests. Pediatr Infect Dis 1997; 16: 1099-1100. 12. Humair J et al.: Management of rapid streptococcal tests and clinical findings. Arch Intern Med 2006; 166: 640-644. 13. DiMatteo L et al.: The relationship between the clinical features of pharyngitis and the sensitivity of a rapid antigen test: evidence spectrum bias. Ann Emer Med 2001; 38: 848-852. 14. Edmonson M, Farwell K: Relationship between the clinical likelihood of group A streptococcal pharyngitis and the sensitivity of a rapid antigen-detection test in a pediatric practice. Pediatrics 2005; 115: 280-285. 15. Gonzales R, Steiner J, Sande M: Antibiotic prescribing for adults with colds, upper respiratory tract infections and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901-904. 16. Butler C et al.: Understanding the culture of prescribing: qualitive study of general practitioners and patients perceptions of antibiotics for sore throats. BMJ 1998; 317: 637-642. 17. Mangione-Smith R et al.: The relationship between perceived parenteral expectations and pediatrician antimicrobial prescribing behavior. Pediatrics 1999; 103: 711-718. 18. Ball P et al.: Consensus group on resistance and prescribing in respiratory tract infection. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrobiol Chemother 2002; 49: 31-40. 19. Zwart S et al.: Penicillin for acute sore throat in children: randomised double blind trial. BMJ 2003; 327: 1324-1329. 20. Dagnelie C et al.: Do patients with sore throat benefit from penicillin? A randomized double-blind placebo-controlled clinical trial with penicillin V in general practice. Br J Gen Pract 1996; 46: 589-593. 21. Del Mar C, Glasziou P, Spinks A: Antibiotics for sore throat. The Cochrane Database of Systemic Reviews 2004, Issue 2 CD000023.pub2. DOI: 10.1002/14651858.CD000023.pub2. 22. Coonan K, Kaplan E: In vitro susceptibility of recent North America group A streptococcal isolates to eleven oral antibiotics. Pediatr Infect Dis J 1994; 13: 630-635. 23. Biedenbach D, Stephen J, Jones R: Antimicrobial susceptibility profile among beta-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program-North America, 2001. Diagn Microbiol Infect Dis 2003; 46: 291-294. 24. Hryniewicz W, Kad-ubowski M, Skoczyńska A: Dane Krajowego Ośrodka Referencyjnego ds. Lekowrażliwości Drobnoustrojów; Narodowy Instytut Zdrowia Publicznego, 2006. 25. Markowitz M, Gerber M, Kaplna E: Treatment of streptococcal pharyngotonsillitis: reports of penicillin´s demise are premature. J Pediatr 1993; 123: 679-685. 26. Adam D, Scholtz H, Helmerking M: Short course antibiotic treatment of 4782 culture proven cases of Group A Streptococcal tonsillopharyngitis and incidence of poststreptococcal sequele. J Infect Dis 2000; 182: 509-516. 27. Denny F et al.: Prevention of rheumatic fever. Treatment of the preceding streptococci infection. JAMA 1950; 143: 151-153. 28. Webb K, Needham C, Kurtz S: Use of a high sensitivity rapid strep test without culture confirmation of negative results: 2 year´s experience. J Fam Pract 2000; 49: 34-38. 29. Randolph M, Gerber M, DeMeo K, Wright L: Effect of antibiotic therapy on the clinical course of streptococcal pharyngitis. J Pediatr 1985; 106: 750-875. 30. Kucers A et al.: The use of the antibiotics. Butterworth-Heinemann 1997. 31. Report of WHO Expert Consultation: Rheumatic fever and rheumatic heart disease. Geneva 2004. 32. Bisno A et al.: IDSA Practice guidelines for the diagnosis and management of group A Streptococcal pharyngitis. Clin Infec Dis 2002; 35: 113-125. 33. Feder H et al.: Once-daily therapy for streptococcal pharyngitis with amoxicillin. Pediatrics 1999; 103: 47-51. 34. Peyramond D et al.: 6-day amoxicillin versus 10-day penicillin V for group A beta-haemolytic streptoccocal acute tonsillitis in adults: a French Multicenter, Open Label, Randomized Study. Scan J Infect Dis 1996; 28: 497-501. 35. Cohen R et al.: Six day amoxicillin vs ten days penicillin V therapy for Group A streptococcal tonsillopharyngitis. Pediatr Infect Dis J 1996; 15: 678-682. 36. Lennon D et al.: Once daily amoxicillin versus twice daily penicillin V In group A beta-hemolytic streptococcal pharyngitis. Arch Dis Child 2008; 93: 474-478. 37. Guillemont D et al.: Low dosage and long treatment duration of beta-lactam. Risk factor for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 365-370. 38. Bogaert D, Groot R, Hermans P: Streptococcus pneumoniae colonization: the key to pneumococcal diseases. Lancet Infect Dis 2004; 4: 144-154. 39. Dagan R et al.: Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-140. 40. Ginsburg C et al.: A controlled comparative study of penicillin V and cefadroxil therapy of group A streptococcal tonsillopharyngitis. J Int Med Res 1980; 8: 82-86. 41. Gerber M et al.: Once daily therapy for streptococcal pharyngitis with cefadroxil. J Pediatr 1986; 108: 531-537. 42. Pichichero M et al.: A multicenter, randomized, single blind evaluation of cefuroxime axetil and phenoxymethyl penicillin in the treatment of streptococcal pharyngitis. Clin Pediatr 1987; 26: 453-458. 43. Mehra S et al.: Short course therapy with cefuroxime axetil for group A streptococcal tonsillopharyngitis in children. Pediatr J Infect Dis 1998; 17: 452-457. 44. Gehanno P, Chichie D: Tonsillopharyngitis: evaluation of short term treatment with cefuroxime axetil versus standard 10-day penicillin V therapy. Br J Clin Pract 1995; 49: 28-32. 45. Aujard Y et al.: Comparative efficacy and safety of four-day cefuroxime axetil and ten-day penicillin treatment of group A beta-hemolytic streptococcal pharyngitis in children. Pediatr Infect Dis J 1995; 14: 295-300. 46. Adam D, Scholz H, Helmerking M: Comparison of short course (5 day) cefuroxime axetil with a standard 10 day oral penicillin V regimen in the treatment of tonsillopharyngitis. J Antimicrob Chemother 2000; 45(Suppl.): 23-30. 47. Thorburn Ch, Knott S, Edwards D: In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and resistant pneumococci and potential to select resistance. Antimicrob Agent Chemother 1998; 42: 1973-1979. 48. Goldstein FW: Penicillin-resistant Streptococcus pneumoniae selection by beta-lactam and non beta-lactam antibiotics. J Antimicrob Chemother 1999; 44: 141-144. 49. Ginsburg C et al.: Erythromycin therapy for group A streptococcal pharyngitis. Am J Dis Child 1984; 138: 536-539. 50. Hovi T, Svahn T, Valtonen V: Twice a day regimen of erythromycin base is effective in the treatment of acute streptococcal pharyngitis. Scand J Infect Dis 1987; 19: 661-666. 51. Still J et al.: Comparison of clarithromycin and penicillin suspensions in the treatment of children with streptococcal pharyngitis and review of currently available alternative antibiotic therapies. Pediatr Infect Dis J 1993; 12(Suppl. 3): 134-141. 52. Stein G: Comparative study of clarithromycin and penicillin V in the treatment of streptococcal pharyngitis. Eur J Clin Microbiol Infect Dis 1991; 10: 949-953. 53. Schaad U, Kellerhals P, Altwegg M: The Swiss Pharyngitis Study Group. Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis. Pediatr Infect Dis J 2002; 21: 304-308. 54. O´Doherty B, Paediatric Azithromycin Study Group: Azithromycin versus penicillin V in the treatment of paediatric patients with acute streptococcal pharyngitis/tonsillitis. Eur J Clin Microbiol Infect Dis 1996; 15: 718-724. 55. Pacifico L et al.: Comparative safety and efficacy of 3-day azithromycin and 10 day penicillin V treatment of group A beta-hemolytic streptococcal pharyngitis in children. Antimicrob Agent Chemother 1996; 40: 1005-1009. 56. Cohen R et al.: Azithromycin versus penicillin V for treatment of acute group A streptococcal pharyngitis. Pediatr Infect Dis J 2002; 21: 297-303. 57. Freeman A, Schulman S: Macrolide resistance in group A streptococcus. Pediatr Infect Dis J 2002; 21: 1158-1160. 58. Nakae M et al.: Drug resistance in Streptococcus pyogenes isolated in Japan. Antimicrob Agent Chemother 1977; 12: 427-428. 59. Bass J et al.: Decline of erythromycin resistance of group A streptococci in Japan. Arch Pediatr Adolesc Med 1994; 148: 67-71. 60. Hryniewicz W, Kad-ubowski M, Skoczyńska A: Dane Krajowego Ośrodka Referencyjnego ds. Lekowrażliwości Drobnoustrojów; Narodowy Instytut Zdrowia Publicznego, 2006. 61. Catanzaro F et al.: The role of streptococcus in the pathogenesis of rheumatic fever. Am J Med 1954; 17: 749-756. 62. Bauchner H, Pelton S, Klein J: Parents, physicians and antibiotics use. Pediatrics 1999; 103: 395-398. 63. Ware J: Rational use of antibiotics for upper respiratory infections: an evidence based approach. Clin Excell Nurse Pract 2000; 4: 151-155. 64. Watson R et al.: Antimicrobial use for pediatric upper respiratory infections: reported practice, actual practice, and parent beliefs. Pediatrics 1999; 104: 1251-1257. 65. Teele D, Klein J, Rosner B: Epidemiology of otitis media during first seven years of life in children in great area Boston: a prospective kohort study. J Infect Dis 1989; 160: 83-94. 66. Armstrong G, Pinner R: Outpatients visits for infectious diseases in the United States, 1980 through 1996. Arch Intern Med 1999; 159: 2531-36. 67. Ruuskanen O et al.: Acute otitis media and respiratory virus infections. Pediatr Infect Dis J 1989; 8: 94-9. 68. Klein B, Dollette F, Yolken R: The role of respiratory syncytial virus and other viral pathogens in acute otitis media. J Pediatr 1998; 101: 16-20. 69. Pitkaranta A et al.: Detection of rhinovirus, respiratory syncytial virus and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction. Pediatrics 1998; 102: 291-5. 70. Bluestone C, Stephenson J, Martin L: Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992; 8: 7-11. 71. Carey J, Pichichero M: Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004; 23: 824-8. 72. Glasziou P, del Mar C, Hayem M: Antibiotics for acute otitis media in children. The Cochrane Database Syst Rev 2004; Issue 1: No. CD000219. 73. Rosenfeld R: What to expect from medical therapy. In: Evidence based otitis media. Rosenfeld R, Bluestone C. eds. Hamilton, Canada: Decker, 1999 pp. 179-205. 74. Burke P et al.: Acute red ear in children: controlled trial of non-antibiotic treatment in general practice. BMJ 1991; 303: 558-62. 75. Mygind N et al.: Penicillin in acute otitis media: a double blind placebo controlled trial. Clin Otolaryngol 1981; 6: 5-13. 76. Burke P et al.: Acute red ear in children: controlled trial of non-antibiotic treatment in general practice. BMJ 1991; 303: 558-62. 77. Mandel E et al.: Efficacy of 20 versus 10 day antimicrobial treatment for acute otitis media. Pediatrics 1995; 96: 5-13. 78. Kaleida P et al.: Amoxicillin-clavulanate potassium compared with cefaclor for acute otitis media in infants and children. Pediatr Infect Dis J 1987; 6: 265-71. 79. Van Buchen F, Peeters M, Van´t Hof M: Acute otitis media a new treatment strategy. BMJ 1985; 290: 1033-7. 80. Koivunen P et al.: Time to development of acute otitis media during an upper respiratory tract infection in children. Pediatr Infect Dis J 1999; 18: 303-5. 81. Niemela M et al.: Lack of specific symptomatology in children with acute otitis media. Pediatr Infect Dis J 1994; 13: 765-8. 82. Heikkinen T, Ruuskanen O: Signs and symptoms predicting acute otitis media. Arch Pediatr Adolesc Med 1985; 139: 721-3. 83. Wald E: Acute otitis media: more trouble with diagnosis. Pediatr Infect Dis J 2003; 22: 103-4. 84. Karma P et al.: Otoscopic diagnosis of middle ear effusion in acute and non-aucte otitis media. Int J Othorhinolaryngol 1989; 17: 37-49. 85. Pelton SI: Otoscopy for the diagnosis of otitis media. Pediatr Infect Dis J 1998; 17: 540-3. 86. Rothman R, Ownes T, Simel D: Does this child have acute otitis media? JAMA 2003; 290: 1633-40. 87. Bluestone C, Cantekin E: Design factors in the characterization and identification of otitis media and certain related conditions. Ann Otol Rhinol Laryngol 1979; 88(Suppl. 60): 13-28. 88. Blomgren K, Pitkaranta A: Is it possible to diagnose acute otitis media accurately in primary health care? Fam Pract 2003; 20: 524-7. 89. Spiro D et al.: A randomized clinical trial to assess the effects of tympanometry on the diagnosis and treatment of acute otitis media. Pediatrics 2004; 114: 177-81. 90. Jensen P, Lous J: Criteria, performance and diagnostics problems in diagnosing acute otitis media. Fam Pract 1999; 16: 262-68. 91. Bertin L et al.: A randomized, double blind, multicentre trial on ibuprofen, acetaminophen and placebo for symptoms of acute otitis media. Fundam Clin Pharmacol 1996; 10: 387-392. 92. Goldman RD et al.: Antypiretic efficacy and safety of ibuprofen and acetamminophen in children. Ann Pharmacother 2004; 38: 146-50. 93. Foxlee R et al.: Topical analgesia for acute otitis media. The Cochrane Database Syst Rev 2006, Issue 3; No: CD005667. 94. Coleman C, Moore M: Decongestants and antihistamines for acute otitis media in children. Cochrane Database of Systematic Rev 2008, Issue 3. Art. No.: CD001727. DOI: 10.1002/14651858.CD001727.pub4. 95. Dagan R et al.: Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 1998; 17: 776-82. 96. Dagan R et al.: Evidence to support the rationale that bacterial eradications is an important aim of antimicrobial therapy. J Antimicrobiol Chemother 2001; 47: 129-40. 97. Ball P et al.: Consensus Group on Resistance and Prescribing in Respiratory Tract Infections. J Antimicrobiol Chemother 2002; 49: 31-40. 98. Rosenfeld R et al.: Clinical efficacy of antimicrobial drugs for acute otitis media: meta-analysis of 5400 children from thirty three randomized trials. J Pediatr 1994; 124: 355-67. 99. Del Mar C, Glasziou P, Hayem M: Are antibiotics indicated as initial treatment for children with acute otitis media. BMJ 1997; 314: 1526. 100. Rovers M et al.: Antibiotics for acute otitis media: a meta-analysis with individual patient data. Lancet 2006; 368: 1429-35. 101. Rovers M et al.: Predictors of pain and/or fever at 3 to 7 days for children with acute otitis media not treated initially with antibiotics: A meta-analysis of individual patient data. Pediatrics 2007; 119: 579-585. 102. Little P et al.: Predictors of poor outcome and benefits from antibiotics in children with acute otitis media: pragmatic randomised trial. BMJ 2002; 325: 1-6. 103. McCormick D et al.: Nonsevere acute otitis media: A clinical trial comparing outcomes of watchful waiting versus immediate antibiotic treatment. Pediatrics 2005; 115: 1455-65. 104. Spiro D et al.: Wait and see prescription for the treatment of acute otitis media. JAMA 2006; 296: 1235-41. 105. Skoczyńska A et al.: Resistance pattern of selected respiratory tract pathogens. Clin Microbiol Infect 2007; 13: 377-8. 106. Dagan R et al.: Bacteriologic response in acute otitis media comparison between azithromycin, cefaclor and amoxicillin. Abstract k-103 In: 37th ICAAC, Toronto Canada 1997. 107. Arguedas A et al.: A randomised multicenter double blind double dummy trial of single dose azithromycin versus high dose amoxicillin for treatment of uncomplicated acute otitis media. Pediatr Infect Dis J 2005; 24: 153-61. 108. Kozyrsykyj A et al.: Short course antibiotics for acute otitis media. The Cochrane Database Syst Rev 2000, Issue 2; Art. No: CD001095. 109. Cohen R et al.: Five versus ten days of antibiotics therapy for acute otitis media in young children. Pediatr Infect Dis J 2000; 19: 458-63. 110. Schrag S, Pena C, Fernandez J: Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001; 286: 49-56.

otrzymano/received: 2009-02-25
zaakceptowano/accepted: 2009-03-27

Adres/address:
*Piotr Albrecht
Klinika Gastroenterologii i Żywienia Dzieci WUM
ul. Działdowska 1, 01-184 Warszawa
tel.: (0-22) 452-32-66, fax: (0-22) 452-33-20
e-mail: palbrecht@kliniczny.pl

Pełna wersja artykułu Optymalizacja antybiotykoterapii zakażeń dróg oddechowych w aspekcie programu ochrony antybiotyków dostępna w Czytelni Medycznej Borgis.

Copyright © Wydawnictwo Medyczne Borgis Sp. z o.o. 2007-2013
Chcesz być na bieżąco? Polub nas na Facebooku: strona Wydawnictwa na Facebooku